




RealRate

PHARMACEUTICAL 2019

Larimar Therapeutics Inc.
Rank 209 of 371



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2019

Larimar Therapeutics Inc. Rank 209 of 371

The relative strengths and weaknesses of Larimar Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Larimar Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 268% points. The greatest weakness of Larimar Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 131% points.

The company's Economic Capital Ratio, given in the ranking table, is -195%, being 136% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	121,330
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	13,306
Liabilities, Non-Current	0
Other Assets	57
Other Compr. Net Income	25
Other Expenses	0
Other Liabilities	15,185
Other Net Income	-246
Property and Equipment	375
Research and Development	47,929
Revenues	0
Selling, General and Administrative Expense	13,193

Output Variable	Value in 1000 USD
Assets	121,762
Liabilities	28,491
Expenses	61,122
Stockholders Equity	93,271
Net Income	-61,368
Comprehensive Net Income	-61,356
Economic Capital Ratio	-195%

